GLP-1 NEWS TODAY

EVIDENCE-BASED MEDICATION EDUCATION
BreakingFDA Approves First Oral GLP-1 for Weight Loss: Wegovy Pill Available January 2026
Breaking News

FDA Approves First Oral GLP-1 for Weight Loss

In a landmark decision, the FDA has approved Wegovy pill—the first oral semaglutide for chronic weight management. Clinical trials show 17% average weight loss without needles. Available January 2026 at $149/month.

FDA Approval•5 min read•December 23, 2025
In-Depth Review

Wegovy Pill: Complete Review & What to Expect

Clinical trial results, dosing schedule, side effects, and how it compares to injections.

Essential Guide

Semaglutide for Weight Loss: Complete Guide

How it works, clinical trial results, and side effects explained.

Editorial Notice

Important: The information provided on GLP-1 News Today is for educational purposes only and should not be considered medical advice.

We are not physicians. This publication serves as a starting point for informed conversations with your healthcare provider. GLP-1 medications require medical supervision and are not appropriate for everyone.

GLP-1 News Today maintains editorial independence. When we link to services, we may earn affiliate commissions that support our research and reporting. All relationships are disclosed on our Affiliate Disclosure page.

Start Your Research

Read our comprehensive guide or compare telehealth providers to find the best option for your situation.

Read Complete Guide →Compare Providers →
Evidence-Based

All claims cited from peer-reviewed research

Transparent

Clear affiliate disclosures & limitations

Independent

Editorial freedom maintained